



Docket No.: 55591 (71699)

0326  
#4  
GP 1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rade, J. et al EXAMINER: unassigned  
SERIAL NO.: 09/863,803 GROUP: unassigned  
FILED: May 22, 2001  
FOR: GENETIC ENGINEERING OF VASCULAR GRAFTS  
TO RESIST DISEASE

THE ASSISTANT COMMISSIONER OF PATENTS  
WASHINGTON, DC 20231

---

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to The Assistant Commissioner for Patents, Washington, D.C. 20231 on July 23, 2001.

By: \_\_\_\_\_

Robert L. Buchanan

---

Sir:


LETTER

The attached information disclosure statement (IDS) includes references that may have been available to the public less than one year or after the priority date of the above-referenced patent application. Such submission is not to be construed as an admission that the references are prior art.

It is believed that consideration of such references by the USPTO will assist understanding of the invention.

Respectfully submitted,

Date: July 23, 2001



---

Robert L. Buchanan (Reg. No. 40,927)  
Edwards & Angell, LLP  
101 Federal Street  
Boston, Massachusetts 02110-1800  
(617-439-4444)

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
55591

In Re Application Of: J. RADE, et al.

Serial No. 09/863,803  
Filing Date May 22, 2001

Examiner  
not yet assigned

Group Art Unit  
not yet assigned

Title: GENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 04-1105 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**


I certify that this document and fee is being deposited on July 25, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Laura M. McGuire

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: July 23, 2001

Robert L. Buchanan (Reg. No. 40,927)  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209

CC:

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
55591

In Re Application Of: J. BADE, et al.

Serial No.  
09/863,800

JUL 30 2001

Filing Date  
May 22, 2001

Examiner  
not yet assigned

Group Art Unit  
not yet assigned

Title: GENETIC ENGINEERING OF VASCULAR GRAFTS TO RESIST DISEASE

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
  2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).